President Donald Trump is reportedly nearing the end of negotiations with drugmakers Eli Lilly and Novo Nordisk to offer the lowest dose of their popular obesity drugs for $149 per month in exchange for Medicare coverage for weight loss.
Preliminary details of the deal, reported by EndPoints News, indicate that Novo Nordisk, the maker of GLP-1s Ozempic and Wegovy, could offer the lowest dose of Wegovy through TrumpRx for as little as $149. In exchange, the government would extend Medicare coverage for Wegovy for weight loss purposes.